SpringerLink
Log in

Calcitonin Gene-Related Peptide and Trigeminal Neuralgia

  • Review
  • Published:
SN Comprehensive Clinical Medicine Aims and scope Submit manuscript

Abstract

Calcitonin gene-related peptide (CGRP) is known to be involved in the pathophysiology of migraine headache. CGRP may play a role in the mechanisms of somatic, visceral, neuropathic, and inflammatory pain. Currently, there are multiple new biologic therapies targeting CGRP which have been approved for the acute and preventive treatment of migraine. Studies have also shown CGRP to be involved in the pathophysiology of trigeminal neuralgia (TN), an often severe and refractory facial pain condition. This article outlines the pathophysiology of trigeminal neuralgia and the role CGRP may play in this condition. We discuss the current evidence on CGRP in trigeminal neuralgia and how modulation of CGRP may be a potential target in the treatment of trigeminal neuralgia in the future. With many similarities in the pathophysiology and efficacy of drug therapies for migraine and trigeminal neuralgia, we hypothesize that targeting CGRP may be a potential mechanism of pain relief in trigeminal neuralgia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Katusic S, Beard CM, Bergstralh E, Kurland LT. Incidence and clinical features of trigeminal neuralgia, Rochester, Minnesota, 1945-1984. Ann Neurol. 1990;27(1):89–95. https://doi.org/10.1002/ana.410270114.

    Article  CAS  PubMed  Google Scholar 

  2. De Toledo IP, Conti Réus J, Fernandes M, Porporatti AL, Peres MA, Takaschima A, Linhares MN, De Luca Canto G. Prevalence of trigeminal neuralgia: a systematic review. J Am Dent Assoc. 2016;147(7):570–576.e572. https://doi.org/10.1016/j.adaj.2016.02.014.

    Article  PubMed  Google Scholar 

  3. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd. (2018). Cephalalgia., 38(1), 1-211. https://doi.org/10.1177/0333102417738202.

  4. Jones MR, Urits I, Ehrhardt KP, Cefalu JN, Kendrick JB, Park DJ, Cornett EM, Kaye AD, Viswanath O. A comprehensive review of trigeminal neuralgia. Curr Pain Headache Rep. 2019;23(10):74. https://doi.org/10.1007/s11916-019-0810-0.

    Article  PubMed  Google Scholar 

  5. Rasmussen P. Facial pain. II. A prospective survey of 1052 patients with a view of: character of the attacks, onset, course, and character of pain. Acta Neurochir. (Wien). 1990;107(3-4):121–8. https://doi.org/10.1007/BF01405790.

    Article  CAS  PubMed  Google Scholar 

  6. Maarbjerg S, Gozalov A, Olesen J, Bendtsen L. Concomitant persistent pain in classical trigeminal neuralgia--evidence for different subtypes. Headache. 2014a;54(7):1173–83. https://doi.org/10.1111/head.12384.

    Article  PubMed  Google Scholar 

  7. Brisman R. Constant face pain in typical trigeminal neuralgia and response to γ knife radiosurgery. Stereotact Funct Neurosurg. 2013;91(2):122–8. https://doi.org/10.1159/000343206.

    Article  PubMed  Google Scholar 

  8. Cruccu G, Finnerup NB, Jensen TS, Scholz J, Sindou M, Svensson P, Treede RD, Nurmikko T. Trigeminal neuralgia: new classification and diagnostic grading for practice and research. Neurology. 2016;87(2):220–8. https://doi.org/10.1212/WNL.0000000000002840.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Brisman R. Trigeminal neuralgia and multiple sclerosis. Arch Neurol. 1987;44(4):379–81. https://doi.org/10.1001/archneur.1987.00520160021008.

    Article  CAS  PubMed  Google Scholar 

  10. Di Stefano G, Maarbjerg S, Truini A. Trigeminal neuralgia secondary to multiple sclerosis: from the clinical picture to the treatment options. J Headache Pain. 2019;20(1):20. https://doi.org/10.1186/s10194-019-0969-0.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Gronseth G, Cruccu G, Alksne J, Argoff C, Brainin M, Burchiel K, Nurmikko T, Zakrzewska JM. Practice parameter: the diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the European Federation of Neurological Societies. Neurology. 2008;71(15):1183–90. https://doi.org/10.1212/01.wnl.0000326598.83183.04.

    Article  CAS  PubMed  Google Scholar 

  12. Maarbjerg S, Gozalov A, Olesen J, Bendtsen L. Trigeminal neuralgia--a prospective systematic study of clinical characteristics in 158 patients. Headache. 2014b;54(10):1574–82. https://doi.org/10.1111/head.12441.

    Article  PubMed  Google Scholar 

  13. Cruccu G. Trigeminal neuralgia. CONTINUUM: Lifelong Learn. in Neurol. 2017;23(2):396–420. https://doi.org/10.1212/CON.0000000000000451.

    Article  Google Scholar 

  14. Cruccu G, Gronseth G, Alksne J, Argoff C, Brainin M, Burchiel K, Nurmikko T, Zakrzewska JM. AAN-EFNS guidelines on trigeminal neuralgia management. Eur J Neurol. 2008;15(10):1013–28. https://doi.org/10.1111/j.1468-1331.2008.02185.x.

    Article  CAS  PubMed  Google Scholar 

  15. Bendtsen L, Zakrzewska JM, Heinskou TB, Hodaie M, Leal PRL, Nurmikko T, Obermann M, Cruccu G, Maarbjerg S. Advances in diagnosis, classification, pathophysiology, and management of trigeminal neuralgia. Lancet Neurol. 2020;19(9):784–96. https://doi.org/10.1016/S1474-4422(20)30233-7.

    Article  CAS  PubMed  Google Scholar 

  16. McQuay HJ, Moore RA, Eccleston C, Morley S, Williams AC. Systematic review of outpatient services for chronic pain control. Health Technol Assess. 1997;1(6):i–iv. https://doi.org/10.3310/hta1060.

  17. Al-Quliti KW. Update on neuropathic pain treatment for trigeminal neuralgia: The pharmacological and surgical options. Neurosciences. (Riyadh). 2015;20(2):107–14. https://doi.org/10.17712/nsj.2015.2.20140501.

    Article  PubMed  Google Scholar 

  18. Montano N, Conforti G, Di Bonaventura R, Meglio M, Fernandez E, Papacci F. Advances in diagnosis and treatment of trigeminal neuralgia. Ther Clin Risk Manag. 2015;11:289–99. https://doi.org/10.2147/TCRM.S37592.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Obermann M. Treatment options in trigeminal neuralgia. Ther Adv Neurol Disord. 2010;3(2):107–15. https://doi.org/10.1177/1756285609359317.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Zhang WB, Min LZ, Tao BB, Sun QY, Li ST, Wang XQ. Prognosis comparison of different branches of trigeminal neuralgia. World Neurosurg. 2020;133:e1–5. https://doi.org/10.1016/j.wneu.2019.06.115.

    Article  PubMed  Google Scholar 

  21. Zhang WB, Zeng YY, Chang BW, Min LZ, Sun QY, Li B, Tao BB, Wang XQ. Prognostic nomogram for microvascular decompression-treated trigeminal neuralgia. Neurosurg Rev. 2021;44(1):571–7. https://doi.org/10.1007/s10143-020-01251-0.

    Article  CAS  PubMed  Google Scholar 

  22. Zheng JH, Sun K, Zhang HT, **e YJ, Wang-Yang LX, Chen HY, Wang C. A study on the recurrence rate of trigeminal neuralgia after MVD and the related factors. J Neurol Surg B Skull Base. 2020;81(5):572–8. https://doi.org/10.1055/s-0039-1692687.

    Article  PubMed  Google Scholar 

  23. Mimeh H, Fenech Magrin AM, Myers S, Ghanem AM. A critical review of botulinum toxin type a in the prophylactic treatment of chronic migraine in adults. Aesthet Surg J. 2019;39(8):898–907. https://doi.org/10.1093/asj/sjy224.

    Article  PubMed  Google Scholar 

  24. Tassorelli C, Sances G, Avenali M, De Icco R, Martinelli D, Bitetto V, Nappi G, Sandrini G. Botulinum toxin for chronic migraine: clinical trials and technical aspects. Toxicon. 2018;147:111–5. https://doi.org/10.1016/j.toxicon.2017.08.026.

    Article  CAS  PubMed  Google Scholar 

  25. Morra ME, Elgebaly A, Elmaraezy A, Khalil AM, Altibi AM, Vu TL, Mostafa MR, Huy NT, Hirayama K. Therapeutic efficacy and safety of botulinum toxin A therapy in trigeminal neuralgia: a systematic review and meta-analysis of randomized controlled trials. J Headache Pain. 2016;17(1):63. https://doi.org/10.1186/s10194-016-0651-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Zhang Y, Lian Y, Zhang H, **e N, Chen Y. CGRP plasma levels decrease in classical trigeminal neuralgia patients treated with botulinum toxin type A: a pilot study. Pain Med. 2020;21(8):1611–5. https://doi.org/10.1093/pm/pnaa028.

    Article  PubMed  Google Scholar 

  27. Kanai A, Saito M, Hoka S. Subcutaneous sumatriptan for refractory trigeminal neuralgia. Headache. 2006;46(4):577–82. https://doi.org/10.1111/j.1526-4610.2006.00405.x.

    Article  PubMed  Google Scholar 

  28. Kanai A, Suzuki A, Osawa S, Hoka S. Sumatriptan alleviates pain in patients with trigeminal neuralgia. Clin J Pain. 2006;22(8):677–80.

    Article  PubMed  Google Scholar 

  29. Shimohata K, Shimohata T, Motegi R, Miyashita K. Nasal sumatriptan as adjunctive therapy for idiopathic trigeminal neuralgia: report of three cases. Headache. 2009;49(5):768–70. https://doi.org/10.1111/j.1526-4610.2008.01254.x.

    Article  PubMed  Google Scholar 

  30. Juhasz G, Zsombok T, Jakab B, Nemeth J, Szolcsanyi J, Bagdy G. Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack. Cephalalgia. 2005;25(3):179–83. https://doi.org/10.1111/j.1468-2982.2005.00836.x.

    Article  CAS  PubMed  Google Scholar 

  31. Halker RB, Vargas BB. Pathophysiology of migraine & triptan mechanism of action. In: Triptans for Migraine. London, England: Future Medicine Ltd; 2012. p. 6–15.

  32. Benemei S, Cortese F, Labastida-Ramírez A, Marchese F, Pellesi L, Romoli M, Vollesen AL, Lampl C, Ashina M. Triptans and CGRP blockade - impact on the cranial vasculature. J Headache Pain. 2017;18(1):103. https://doi.org/10.1186/s10194-017-0811-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Amara SG, Jonas V, Rosenfeld MG, Ong ES, Evans RM. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature. 1982;298(5871):240–4. https://doi.org/10.1038/298240a0.

    Article  ADS  CAS  PubMed  Google Scholar 

  34. Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010;6(10):573–82. https://doi.org/10.1038/nrneurol.2010.127.

    Article  CAS  PubMed  Google Scholar 

  35. Tepper SJ. History and review of anti-calcitonin gene-related peptide (CGRP) therapies: from translational research to treatment. Headache. 2018;58(Suppl 3):238–75. https://doi.org/10.1111/head.13379.

    Article  PubMed  Google Scholar 

  36. Yuan H, Spare NM, Silberstein SD. Targeting CGRP for the prevention of migraine and cluster headache: a narrative review. Headache. 2019;59(Suppl 2):20–32. https://doi.org/10.1111/head.13583.

    Article  PubMed  Google Scholar 

  37. Schou WS, Ashina S, Amin FM, Goadsby PJ, Ashina M. Calcitonin gene-related peptide and pain: a systematic review. J Headache Pain. 2017;18(1):34. https://doi.org/10.1186/s10194-017-0741-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553–622. https://doi.org/10.1152/physrev.00034.2015.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Eftekhari S, Warfvinge K, Blixt FW, Edvinsson L. Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system. J Pain. 2013;14(11):1289–303. https://doi.org/10.1016/j.jpain.2013.03.010.

    Article  CAS  PubMed  Google Scholar 

  40. Edvinsson L, Fredholm BB, Hamel E, Jansen I, Verrecchia C. Perivascular peptides relax cerebral arteries concomitant with stimulation of cyclic adenosine monophosphate accumulation or release of an endothelium-derived relaxing factor in the cat. Neurosci Lett. 1985;58(2):213–7. https://doi.org/10.1016/0304-3940(85)90166-1.

    Article  CAS  PubMed  Google Scholar 

  41. Messlinger K, Lennerz JK, Eberhardt M, Fischer MJ. CGRP and NO in the trigeminal system: mechanisms and role in headache generation. Headache. 2012;52(9):1411–27. https://doi.org/10.1111/j.1526-4610.2012.02212.x.

    Article  PubMed  Google Scholar 

  42. Messlinger K. The big CGRP flood - sources, sinks and signalling sites in the trigeminovascular system. J Headache Pain. 2018;19(1):22. https://doi.org/10.1186/s10194-018-0848-0.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Noseda R, Jakubowski M, Kainz V, Borsook D, Burstein R. Cortical projections of functionally identified thalamic trigeminovascular neurons: implications for migraine headache and its associated symptoms. J Neurosci. 2011;31(40):14204–17. https://doi.org/10.1523/JNEUROSCI.3285-11.2011.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Lennerz JK, Rühle V, Ceppa EP, Neuhuber WL, Bunnett NW, Grady EF, Messlinger K. Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution. J Comp Neurol. 2008;507(3):1277–99. https://doi.org/10.1002/cne.21607.

    Article  CAS  PubMed  Google Scholar 

  45. Eftekhari S, Salvatore CA, Johansson S, Chen TB, Zeng Z, Edvinsson L. Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood-brain barrier. Brain Res. 2015;1600:93–109. https://doi.org/10.1016/j.brainres.2014.11.031.

    Article  CAS  PubMed  Google Scholar 

  46. Pannese E. The satellite cells of the sensory ganglia. Adv Anat Embryol Cell Biol. 1981;65:1–111. https://doi.org/10.1007/978-3-642-67750-2.

    Article  CAS  PubMed  Google Scholar 

  47. Pannese E, Ledda M, Cherkas PS, Huang TY, Hanani M. Satellite cell reactions to axon injury of sensory ganglion neurons: increase in number of gap junctions and formation of bridges connecting previously separate perineuronal sheaths. Anat Embryol. (Berl). 2003;206(5):337–47. https://doi.org/10.1007/s00429-002-0301-6.

    Article  CAS  PubMed  Google Scholar 

  48. Hanani M. Satellite glial cells in sensory ganglia: from form to function. Brain Res Brain Res Rev. 2005;48(3):457–76. https://doi.org/10.1016/j.brainresrev.2004.09.001.

    Article  CAS  PubMed  Google Scholar 

  49. Vit JP, Jasmin L, Bhargava A, Ohara PT. Satellite glial cells in the trigeminal ganglion as a determinant of orofacial neuropathic pain. Neuron Glia Biol. 2006;2(4):247–57. https://doi.org/10.1017/s1740925x07000427.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Thalakoti S, Patil VV, Damodaram S, Vause CV, Langford LE, Freeman SE, Durham PL. Neuron-glia signaling in trigeminal ganglion: implications for migraine pathology. Headache. 2007;47(7):1008–23. https://doi.org/10.1111/j.1526-4610.2007.00854.x.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Afroz S, Arakaki R, Iwasa T, Oshima M, Hosoki M, Inoue M, Baba O, Okayama Y, Matsuka Y. CGRP induces differential regulation of cytokines from satellite glial cells in trigeminal ganglia and orofacial nociception. Int J Mol Sci. 2019;20(3):711. https://doi.org/10.3390/ijms20030711.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Hay DL, Poyner DR, Sexton PM. GPCR modulation by RAMPs. Pharmacol Ther. 2006;109(1-2):173–97. https://doi.org/10.1016/j.pharmthera.2005.06.015.

    Article  CAS  PubMed  Google Scholar 

  53. Walker CS, Hay DL. CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors? Br J Pharmacol. 2013;170(7):1293–307. https://doi.org/10.1111/bph.12129.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Christopoulos A, Christopoulos G, Morfis M, Udawela M, Laburthe M, Couvineau A, Kuwasako K, Tilakaratne N, Sexton PM. Novel receptor partners and function of receptor activity-modifying proteins. J Biol Chem. 2003;278(5):3293–7. https://doi.org/10.1074/jbc.C200629200.

    Article  CAS  PubMed  Google Scholar 

  55. Walker CS, Eftekhari S, Bower RL, Wilderman A, Insel PA, Edvinsson L, Waldvogel HJ, Jamaluddin MA, Russo AF, Hay DL. A second trigeminal CGRP receptor: function and expression of the AMY1 receptor. Ann Clin Transl Neurol. 2015;2(6):595–608. https://doi.org/10.1002/acn3.197.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Love S, Coakham HB. Trigeminal neuralgia: pathology and pathogenesis. Brain. 2001;124(Pt 12):2347–60. https://doi.org/10.1093/brain/124.12.2347.

    Article  CAS  PubMed  Google Scholar 

  57. Maarbjerg S, Di Stefano G, Bendtsen L, Cruccu G. Trigeminal neuralgia - diagnosis and treatment. Cephalalgia. 2017;37(7):648–57. https://doi.org/10.1177/0333102416687280.

    Article  PubMed  Google Scholar 

  58. Rappaport HZ, Devor M. Trigeminal neuralgia: the role of self-sustaining discharge in the trigeminal ganglion. Pain. 1994;56(2):127–38. https://doi.org/10.1016/0304-3959(94)90086-8.

    Article  PubMed  Google Scholar 

  59. Devor M, Amir R, Rappaport ZH. Pathophysiology of trigeminal neuralgia: the ignition hypothesis. Clin J Pain. 2002;18(1):4–13. https://doi.org/10.1097/00002508-200201000-00002.

    Article  PubMed  Google Scholar 

  60. Cruccu G, Di Stefano G, Truini A. Trigeminal neuralgia. N Engl J Med. 2020;383(8):754–62. https://doi.org/10.1056/NEJMra1914484.

    Article  PubMed  Google Scholar 

  61. Tajti J, Uddman R, Möller S, Sundler F, Edvinsson L. Messenger molecules and receptor mRNA in the human trigeminal ganglion. J Auton Nerv Syst. 1999;76(2-3):176–83. https://doi.org/10.1016/s0165-1838(99)00024-7.

    Article  CAS  PubMed  Google Scholar 

  62. Ashina M. Migraine. N Engl J Med. 2020;383(19):1866–76. https://doi.org/10.1056/NEJMra1915327.

    Article  CAS  PubMed  Google Scholar 

  63. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28(2):183–7. https://doi.org/10.1002/ana.410280213.

    Article  CAS  PubMed  Google Scholar 

  64. van Dongen RM, Zielman R, Noga M, Dekkers OM, Hankemeier T, van den Maagdenberg AM, Terwindt GM, Ferrari MD. Migraine biomarkers in cerebrospinal fluid: a systematic review and meta-analysis. Cephalalgia. 2017;37(1):49–63. https://doi.org/10.1177/0333102415625614.

    Article  PubMed  Google Scholar 

  65. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia. 2002;22(1):54–61. https://doi.org/10.1046/j.1468-2982.2002.00310.x.

    Article  CAS  PubMed  Google Scholar 

  66. Edvinsson L. The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. Headache. 2017;57(Suppl 2):47–55. https://doi.org/10.1111/head.13081.

    Article  PubMed  Google Scholar 

  67. Limmroth V, Katsarava Z, Liedert B, Guehring H, Schmitz K, Diener HC, Michel MC. An in vivo rat model to study calcitonin gene related peptide release following activation of the trigeminal vascular system. Pain. 2001;92(1-2):101–6. https://doi.org/10.1016/s0304-3959(00)00475-9.

    Article  CAS  PubMed  Google Scholar 

  68. Iyengar S, Ossipov MH, Johnson KW. The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine. Pain. 2017;158(4):543–59. https://doi.org/10.1097/j.pain.0000000000000831.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Qin ZL, Yang LQ, Li N, Yue JN, Wu BS, Tang YZ, Guo YN, Lai GH, Ni JX. Clinical study of cerebrospinal fluid neuropeptides in patients with primary trigeminal neuralgia. Clin Neurol Neurosurg. 2016;143:111–5. https://doi.org/10.1016/j.clineuro.2016.02.012.

    Article  PubMed  Google Scholar 

  70. Michot B, Bourgoin S, Viguier F, Hamon M, Kayser V. Differential effects of calcitonin gene-related peptide receptor blockade by olcegepant on mechanical allodynia induced by ligation of the infraorbital nerve vs the sciatic nerve in the rat. Pain. 2012;153(9):1939–48. https://doi.org/10.1016/j.pain.2012.06.009.

    Article  CAS  PubMed  Google Scholar 

  71. Michot B, Kayser V, Hamon M, Bourgoin S. CGRP receptor blockade by MK-8825 alleviates allodynia in infraorbital nerve-ligated rats. Eur J Pain. 2015;19(2):281–90. https://doi.org/10.1002/ejp.616.

    Article  CAS  PubMed  Google Scholar 

  72. **ong W, Wu RP, Tan MX, Tong ZJ, He LK, Guan S, Liu LJ, Yin CC, Shen YL, Ge HX, Gao Y. Emodin inhibits the expression of receptor and calcitonin-gene-related peptide release in trigeminal ganglia of trigeminal neuralgia rats. Int J Clin Exp Pathol. 2017;10(11):11317–25.

    PubMed  PubMed Central  Google Scholar 

  73. Watkins LR, Milligan ED, Maier SF. Glial activation: a driving force for pathological pain. Trends Neurosci. 2001;24(8):450–5. https://doi.org/10.1016/s0166-2236(00)01854-3.

    Article  CAS  PubMed  Google Scholar 

  74. Yang YJ, Hu L, **a YP, Jiang CY, Miao C, Yang CQ, Yuan M, Wang L. Resveratrol suppresses glial activation and alleviates trigeminal neuralgia via activation of AMPK. J Neuroinflammation. 2016;13(1):84. https://doi.org/10.1186/s12974-016-0550-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Parascandolo E, Levinson K, Rizzoli P, Sharon R. Efficacy of erenumab in the treatment of trigeminal neuralgia: a retrospective case series. Neurol: Clin Pract. 2021;11(3):227–31. https://doi.org/10.1212/cpj.0000000000001075.

    Article  PubMed  Google Scholar 

  76. Schott Andersen AS, Maarbjerg S, Noory N, Heinskou TB, Forman JL, Cruccu G, Ashina M, Bendtsen L. Safety and efficacy of erenumab in patients with trigeminal neuralgia in Denmark: a double-blind, randomised, placebo-controlled, proof-of-concept study. Lancet Neurol. 2022;21(11):994–1003. https://doi.org/10.1016/S1474-4422(22)00294-0.

    Article  CAS  PubMed  Google Scholar 

Download references

Data Availability

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Code Availability

Not applicable.

Author information

Authors and Affiliations

  1. Tel Aviv University, Tel Aviv, Israel

    Rachel Retsky

  2. Department of Neurology and Anesthesia, Pain Medicine and Critical Care, Harvard Medical School, Beth Israel Deaconess Medical Center, MA, Boston, USA

    Sait Ashina

  3. Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark

    Sait Ashina

  4. Ramat-Aviv Medical Center, Tel Aviv, Israel

    Daniel Oved

  5. Sheba Medical Center Department of Headache and Facial pain, Ramat Gan, Israel

    Roni Sharon

Authors
  1. Rachel Retsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sait Ashina
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniel Oved
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Roni Sharon
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Roni Sharon, M. D., identified the idea for this work. Rachel Retsky, B. S., conducted the literature search and wrote the first draft of the manuscript. Roni Sharon, M. D.; Sait Ashina, M. D.; Daniel Oved, M. D.; and Rachel Retsky, B. S., edited the previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Rachel Retsky.

Ethics declarations

Ethics Approval

Not applicable.

Consent to Participate

Not applicable.

Consent for Publication

Not applicable.

Conflict of Interest

Sait Ashina (S. A.) received honoraria for consulting from Allergan/AbbVie, Amgen, Biohaven, Eli Lilly, Impel, NeuroPharma, Novartis, Satsuma, Supernus, Theranica, and Percept. Roni Sharon has been a paid speaker or consultant for the following companies: Novartis, Abbvie, Pfizer, Teva, Eli Lilly, Theranica, Neurolief, BOL, GLG, Guidepoint. Rachel Retsky and Daniel Oved declare that they have no conflicts of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Medicine

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Retsky, R., Ashina, S., Oved, D. et al. Calcitonin Gene-Related Peptide and Trigeminal Neuralgia. SN Compr. Clin. Med. 5, 75 (2023). https://doi.org/10.1007/s42399-023-01407-1

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s42399-023-01407-1

Keywords

Search

Navigation